|
|
|
|

* Pennington Biomedical Research Center, Division of Nutrition and Chronic Diseases, Louisiana State University System, Baton Rouge, LA and
University of Alberta, Metabolic and Cardiovascular Diseases Laboratory, Department of Agricultural, Food and Nutritional Science, Edmonton, AB, Canada
2 To whom correspondence should be addressed. E-mail: cefaluwt{at}pbrc.edu.
Chromium is one of the few trace minerals for which a specific cellular mechanism of action has not been identified. Recent in vitro studies suggest that chromium supplementation may improve insulin sensitivity by enhancing insulin receptor signaling, but this has not been demonstrated in vivo. We investigated the effect of chromium supplementation on insulin receptor signaling in an insulin-resistant rat model, the JCR:LA-corpulent rat. Male JCR:LA-cp rats (4 mo of age) were randomly assigned to receive chromium picolinate (CrPic) (obese n = 6, lean n = 5) or vehicle (obese n = 5, lean n = 5) for 3 mo. The CrPic was provided in the water, and based on calculated water intake, rats randomized to CrPic received 80 µg/(kg·d). At the end of the study, skeletal muscle (vastus lateralis) biopsies were obtained at baseline and at 5, 15, and 30 min postinsulin stimulation to assess insulin signaling. Obese rats treated with CrPic had significantly improved glucose disposal rates and demonstrated a significant increase in insulin-stimulated phosphorylation of insulin receptor substrate (IRS)-1 and phosphatidylinositol (PI)-3 kinase activity in skeletal muscle compared with obese controls. The increase in cellular signaling was not associated with increased protein levels of the IRS proteins, PI-3 kinase or Akt. However, protein tyrosine phosphatase 1B (PTP1B) levels were significantly lower in obese rats administered CrPic than obese controls. When corrected for protein content, PTP1B activity was also significantly lower in obese rats administered CrPic than obese controls. Our data suggest that chromium supplementation of obese, insulin-resistant rats may improve insulin action by enhancing intracellular signaling.
KEY WORDS: cellular signaling chromium obesity insulin resistance
This article has been cited by other articles:
![]() |
Z. Q. Wang, Z. E. Floyd, J. Qin, X. Liu, Y. Yu, X. H. Zhang, J. D. Wagner, and W. T. Cefalu Modulation of Skeletal Muscle Insulin Signaling With Chronic Caloric Restriction in Cynomolgus Monkeys Diabetes, July 1, 2009; 58(7): 1488 - 1498. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Dong, M. R. Kandadi, J. Ren, and N. Sreejayan Chromium (D-phenylalanine)3 Supplementation Alters Glucose Disposal, Insulin Signaling, and Glucose Transporter-4 Membrane Translocation in Insulin-Resistant Mice J. Nutr., October 1, 2008; 138(10): 1846 - 1851. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Q. Wang, W. T. Cefalu, X. H. Zhang, Y. Yu, J. Qin, L. Son, P. M. Rogers, N. Mashtalir, J. R. Bordelon, J. Ye, et al. Human Adenovirus Type 36 Enhances Glucose Uptake in Diabetic and Nondiabetic Human Skeletal Muscle Cells Independent of Insulin Signaling Diabetes, July 1, 2008; 57(7): 1805 - 1813. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Horvath, L. Tackett, A. M. McCarthy, P. Raman, J. T. Brozinick, and J. S. Elmendorf Antidiabetogenic Effects of Chromium Mitigate Hyperinsulinemia-Induced Cellular Insulin Resistance via Correction of Plasma Membrane Cholesterol Imbalance Mol. Endocrinol., April 1, 2008; 22(4): 937 - 950. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rink, S. Roy, S. Khanna, T. Rink, D. Bagchi, and C. K. Sen Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium Physiol Genomics, November 21, 2006; 27(3): 370 - 379. [Abstract] [Full Text] [PDF] |
||||